HCA Healthcare UK has delivered its first Tumour-Infiltrating Lymphocyte (TIL) therapy for a patient with metastatic lung cancer through a clinical trial at the Sarah Cannon Research Institute UK. This development marks a significant advancement in the availability of cell-based immunotherapies within the UK’s private healthcare system.
What is TIL therapy?
TIL therapy uses a patient’s own immune cells extracted from their tumour. These cells are grown and multiplied in the laboratory before being re-infused into the patient to attack cancer cells more effectively. The approach has shown promise for patients with advanced solid tumours where other treatments may be limited.
Clinical significance
– Among the first uses of TIL therapy for lung cancer patients in the UK.
– Conducted within a controlled clinical trial to evaluate safety and outcomes.
– Part of HCA UK’s expanding research into advanced immuno-oncology, alongside CAR-T therapy and targeted treatments.
The delivery of TIL therapy reflects the broader momentum of immuno-oncology innovation. For patients with metastatic lung cancer, cell-based therapies may represent a crucial step beyond chemotherapy, radiotherapy, and existing targeted therapies.
Quick Reference Links
– HCA Healthcare UK
– Sarah Cannon Research Institute UK
– The Harley Street Clinic
